Elabela in Lipid-Related Cardiometabolic Dysfunction: A Critical Narrative Review
Chęcińska-Maciejewska Z., Pruszyńska-Oszmałek E., Kołodziejski P., Ciborek A., Krauss H.
Narrative Review on Type 2 Diabetes, Scar, Chronic Inflammation, published in Metabolites (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Metabolites (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42346388
- PMCID
- PMC13303539
- DOI
- 10.3390/metabo16060408
Abstract (original English)
Elabela (ELA/APELA/Toddler) is an endogenous peptide ligand of the apelin receptor APLNR (also known as APJ) and, together with apelin, forms the apelinergic signalling system. Its role in embryonic development, the cardiovascular system, the kidneys and the endothelium is becoming increasingly well characterised, whilst its function in metabolic regulation remains unresolved. Elabela activates pathways essential for metabolic homeostasis-PI3K/Akt, AMPK-related pathways, redox regulation, inflammatory control and pro-survival cascades-but no study has shown that it directly regulates adipocyte lipid metabolism. This narrative review categorises the evidence at the receptor, organ, immunometabolic and intra-adipocyte levels, and also considers the adipose tissue microenvironment as a distinct level of potential relevance. The available data support a role for Elabela as a candidate mediator of lipid-related metabolic dysfunction-via anti-inflammatory, antioxidant and tissue-protective mechanisms-with macrophage lipid metabolism representing the most informative immunometabolic interface. Human studies remain scarce, heterogeneous and limited by a lack of standardisation in assay methods and the unresolved specificity of isoforms. Elabela should therefore be regarded as a candidate indirect modulator of metabolic homeostasis and a candidate biomarker of cardiometabolic stress or
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol